Denatimab and Early Symptomatic Alzheimer's Disease, the Trailblazer-Alz-2 Randomized Trial

JAMA Editor's Summary is a review of important research, viewpoints, and review articles appearing in the latest JAMA issue. Dr. Kirsten Bippens-Domingo: I hope you find this week's issue beneficial. The first original research article by Dr. Sims and colleagues is titled, Denatimab and Early Symptomatic Alzheimer's Disease; Trailblazer-Alz-2 randomized trial. In both the subgroup of participants with lower medium tau pathology and the overall group including all grades of tau pathology,Denatimab was superior to placebo in the change in integrated Alzheimer's disease rating scale.